S.L.E. LIMITED

Company number 01649988 ·

Active

This analysis was written by an AI from the company's public filings. It may contain errors or omissions and is not financial or professional advice.

Based on the provided data, here is a comprehensive financial health assessment of S.L.E. LIMITED.

Financial Health Score: B+ (Good)

Explanation: S.L.E. LIMITED demonstrates a strong, well-established financial profile. The company shows consistent year-on-year growth in revenue, profitability, and net assets, indicating a healthy and expanding business. Its liquidity position is stable, and it operates with a manageable level of debt. The primary factors preventing a higher grade (A) are the inherent risks in its sector (regulatory changes, global economic uncertainty) and the reliance on a single, albeit strong, product line for growth. The company is in good health with a positive outlook, but must remain vigilant against external headwinds.


1. Key Vital Signs & Their Interpretation

Vital Sign 2016 2017 2018 2019 Trend Interpretation
Net Assets £6.7M £7.5M £8.4M £10.0M 📈 Strong Growth Excellent. A consistently rising net asset value is a classic sign of a company building long-term value and financial strength. This is the company's "equity cushion" against potential losses.
Total Assets £8.7M £9.5M £10.5M £11.7M 📈 Steady Growth Good. The company is growing its resource base, which is a positive sign for future capacity and sales.
Total Liabilities £1.1M £1.4M £1.4M £1.6M 📈 Slight Increase Manageable. Liabilities are growing but at a much slower rate than assets. The company is not becoming dangerously leveraged.
Cash £694K £795K £735K £867K 📈 Stable & Growing Healthy. A stable and growing cash balance is the "lifeblood" of the business. It provides a buffer for operations, R&D investment, and unexpected expenses.
Asset-to-Liability Ratio 7.6 7.0 7.2 7.1 📉 Stable Very Strong. For every £1 of debt, the company holds over £7 in assets. This indicates very low financial risk and a strong ability to meet its obligations.

Summary of Vital Signs: - Pulse (Growth): Strong and steady. Turnover increased by 8.5% and profitability by 25% in the most recent year. - Blood Pressure (Leverage): Low and healthy. The company is not over-reliant on debt. - Blood Count (Liquidity): Stable and adequate. Cash levels are sufficient to cover short-term operational needs, though the strategic report notes liquidity is a managed risk due to R&D and inventory stockpiling.


2. Diagnosis: What the Financial Data Reveals

Primary Diagnosis: Healthy, Growing, and Profitable Enterprise

S.L.E. LIMITED is a financially robust company in a strong growth phase. The core metrics point to a well-managed business with a successful product (SLE6000) that is driving revenue and profit growth.

Symptoms & Underlying Health: - Symptom: Rising Turnover & Profit. This is the primary indicator of health. The 8.5% increase in sales and 25% increase in net profit demonstrate that the company's products are in demand and its operations are becoming more efficient. - Symptom: Strong Balance Sheet. The steady increase in net assets and very high asset-to-liability ratio indicate a low-risk financial structure. The company is funding its growth primarily through retained earnings, which is the hallmark of a sustainable business. - Symptom: Significant R&D Investment (7% of turnover). This is a sign of a company investing in its future, but it's also a "strain" on current liquidity. It is a calculated risk to maintain a competitive edge in a technology-driven market. - Symptom: Increased Inventory & Customer Payment Delays. The strategic report mentions stockpiling for Brexit and large orders, and customers adhering to payment terms. These are "manageable conditions" that can temporarily tie up cash, but they are not critical threats.

Areas Requiring Monitoring (Minor Ailments): - Liquidity Management: The company explicitly identifies liquidity as a risk. While the cash position is stable, the simultaneous demands of R&D, inventory build-up, and slow customer payments create a constant need for careful cash flow management. - Regulatory & Market Risks: The transition from MDD to MDR and uncertainties in global markets (Brexit, China) are external factors that could cause operational delays and increase costs. These are industry-wide challenges, not specific failures of the company.


3. Recommendations to Improve & Maintain Financial Wellness

  1. Strengthen the "Cash Conversion Cycle": The company should focus on reducing customer payment days (54 days). Implementing stricter credit control measures, offering early payment discounts, or using invoice financing could accelerate cash inflows, reducing the strain from inventory stockpiling.

  2. Diversify the "Revenue Stream": While the SLE6000 is a success story, over-reliance on a single product line is a concentration risk. Continue to invest in R&D (as planned) and actively pursue regulatory approvals in key markets like China to broaden the revenue base and reduce dependency on any single market or product.

  3. Formalize Brexit & MDR Contingency Planning: The company has acknowledged these risks. The next step is to ensure there are formal, quantified contingency plans. This includes stress-testing cash flow against scenarios like a "no-deal" Brexit or a significant MDR compliance cost overrun, ensuring the company has a clear action plan for each.

  4. Maintain Open Banking Relationship: The company has a good relationship with its bank. It should proactively communicate its growth plans and potential cash flow needs (e.g., for a major new product launch) to ensure continued access to flexible financing if needed.



Perspective: Financial Health Diagnostician · Model: deepseek/deepseek-v4-flash · Generated 10 November 2026